Theravance Biopharma (NASDAQ:TBPH) has been downgraded from Neutral to Underperform in a report by Bank of America (Merrill Lynch) today.
- Updated: September 18, 2016
Displaying a price of $27.26, Theravance Biopharma (NASDAQ:TBPH) traded 2.42% higher on the day. The last stock close is up 46.25% from the 200-day average, compared with the S&P 500 which has decreased -0.01% over the same period. Theravance Biopharma has recorded a 50-day moving average of $27.38 and 200-day moving average of $22.56. Volume of trade was was up over the average, with 432,451 shares of TBPH changing hands over the typical 253,141 shares.
Bank of America (Merrill Lynch) has downgraded Theravance Biopharma(NASDAQ:TBPH) from Neutral to Underperform in a report released 8/03/2016.
On 5/12/2016, Leerink Swann released a statement about Theravance Biopharma(NASDAQ:TBPH) raised the target price from $0.00 to $26.00 that indicated a possible upside of 0.48%.
In addition to Bank of America (Merrill Lynch) reporting it’s price target, a total of 1 broker has reported on the stock. The 12-month target is $19.00 with one firm rating the company a strong buy, 0 rating the company a buy, one firm rating the stock a hold, 0 rating the stock to underperform, and finally 0 brokerages rating the stock as sell.
With a total market value of $0.0, Theravance Biopharma has a 52 week low of $10.56 and a 52 week high of $33.32 with a PE ratio of 0.
Brief Synopsis On Theravance Biopharma (NASDAQ:TBPH)
Theravance Biopharma, Inc. is a biopharmaceutical company. The Company is engaged in creating medicines that make a difference in the lives of patients suffering from serious illness. The Company operates in the segment of discovery (research), and development and commercialization of human therapeutics. The Company’s pipeline of internally discovered product candidates includes medicines to address the unmet needs of patients being treated for serious conditions primarily in the acute care setting. Its commercial product VIBATIV (telavancin) is a once-daily dual-mechanism antibiotic approved in the United States and Europe for certain difficult-to-treat infections. Revefenacin (TD-4208) is a long-acting muscarinic antagonist (LAMA) being developed as a nebulized treatment for chronic obstructive pulmonary disease. Its neprilysin (NEP) inhibitor program is designed to develop selective NEP inhibitors for the treatment of a range of cardiovascular and renal diseases.
Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with MarketBeat.com's FREE daily email newsletter.